This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hikida, M.
Right arrow Articles by Kitamura, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hikida, M.
Right arrow Articles by Kitamura, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1999, p. 2010-2016, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

In Vitro Antibacterial Activity of LJC 11,036, an Active Metabolite of L-084, a New Oral Carbapenem Antibiotic with Potent Antipneumococcal Activity

Muneo Hikida,* Kouju Itahashi, Atsumi Igarashi, Toshiharu Shiba, and Masataka Kitamura

Medical Research Laboratories, Lederle (Japan), Ltd., Shiki-shi, Saitama-ken 353-8511, Japan

Received 31 December 1998/Returned for modification 19 April 1999/Accepted 4 June 1999

LJC 11,036 is the active metabolite of L-084, a novel oral carbapenem that exhibits potent broad-spectrum activity. Antibacterial activities of LJC 11,036 against clinical isolates from respiratory infections, such as Streptococcus pneumoniae (n = 52), Streptococcus pyogenes (n = 19), Haemophilus influenzae (n = 50), Klebsiella pneumoniae (n = 53), and Moraxella catarrhalis (n = 53), and from urinary-tract infections, such as Escherichia coli (n = 53) (MICs at which 90% of the isolates were inhibited [MIC90s], 0.1, <= 0.006, 0.39, 0.05, 0.05, and 0.05 µg/ml, respectively), were 2- to 64-fold higher than those of imipenem, cefdinir, and faropenem. Moreover, against these bacterial species, except for H. influenzae, the MIC90s of LJC 11,036 were 4- to 512-fold lower than those of levofloxacin. LJC 11,036 showed bactericidal activity equal or superior to that of imipenem. Bactericidal activity against penicillin-resistant S. pneumoniae (PRSP) did not vary with the phase of growth. LJC 11,036 had potent activity against various beta -lactamase-producing strains, excluding carbapenemase producers. Against renal dehydropeptidase-I, LJC 11,036 was more stable than imipenem. Furthermore, LJC 11,036 produced in vitro postantibiotic sub-MIC effects against PRSP HSC-3 (6.0 h at one-fourth the MIC) and H. influenzae LJ5 (9.2 h at one-half the MIC). LJC 11,036 showed high binding affinities for PBP1A, -1B, -2A/2X, -2B, and -3 of PRSP and for PBP1B, -2, -3A, and -3B of H. influenzae.

* Corresponding author. Mailing address: Medical Research Laboratories, Lederle (Japan), Ltd., 1-6-34 Kashiwa-cho, Shiki-shi, Saitama-ken 353-8511, Japan. Phone: (048) 487-6622. Fax: (048) 474-1598.

Antimicrobial Agents and Chemotherapy, August 1999, p. 2010-2016, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Livermore, D. M. (2009). Has the era of untreatable infections arrived?. J Antimicrob Chemother 64: i29-i36 [Abstract] [Full Text]  
  • Yamada, M., Watanabe, T., Baba, N., Takeuchi, Y., Ohsawa, F., Gomi, S. (2008). Crystal Structures of Biapenem and Tebipenem Complexed with Penicillin-Binding Proteins 2X and 1A from Streptococcus pneumoniae. Antimicrob. Agents Chemother. 52: 2053-2060 [Abstract] [Full Text]  
  • Takahata, S., Kato, Y., Sanbongi, Y., Maebashi, K., Ida, T. (2008). Comparison of the Efficacies of Oral {beta}-Lactams in Selection of Haemophilus influenzae Transformants with Mutated ftsI Genes. Antimicrob. Agents Chemother. 52: 1880-1883 [Abstract] [Full Text]  
  • Gettig, J. P, Crank, C. W, Philbrick, A. H (2008). Faropenem Medoxomil. The Annals of Pharmacotherapy 42: 80-90 [Abstract] [Full Text]  
  • Kobayashi, R., Konomi, M., Hasegawa, K., Morozumi, M., Sunakawa, K., Ubukata, K. (2005). In Vitro Activity of Tebipenem, a New Oral Carbapenem Antibiotic, against Penicillin-Nonsusceptible Streptococcus pneumoniae. Antimicrob. Agents Chemother. 49: 889-894 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T. (2002). Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites. J Antimicrob Chemother 50: 411-420 [Abstract] [Full Text]  
  • von Eiff, C., Schepers, S., Peters, G. (2002). Comparative in vitro activity of faropenem against staphylococci. J Antimicrob Chemother 50: 277-280 [Abstract] [Full Text]  
  • Miyazaki, S., Hosoyama, T., Furuya, N., Ishii, Y., Matsumoto, T., Ohno, A., Tateda, K., Yamaguchi, K. (2001). In Vitro and In Vivo Antibacterial Activities of L-084, a Novel Oral Carbapenem, against Causative Organisms of Respiratory Tract Infections. Antimicrob. Agents Chemother. 45: 203-207 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»